XSTOELIC
Market cap5mUSD
Dec 23, Last price
1.72SEK
1D
-2.27%
1Q
9.55%
IPO
-70.47%
Name
Elicera Therapeutics AB
Chart & Performance
P/E
—
P/S
5.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.46%
Rev. gr., 5y
%
Revenues
11m
+777.23%
Net income
-16m
L-15.97%
CFO
-15m
L+74.11%
Earnings
May 16, 2025
Profile
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 11,230 777.23% | 1,280 217,987.39% | 587 | |||||||
Cost of revenue | 12 | 8,969 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 11,230 | 1,268 | (8,968) | |||||||
NOPBT Margin | 100.00% | 99.08% | ||||||||
Operating Taxes | 76 | 1 | ||||||||
Tax Rate | 5.98% | |||||||||
NOPAT | 11,230 | 1,193 | (8,969) | |||||||
Net income | (16,398) -15.97% | (19,515) 48.72% | (13,122) 365.68% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 55,122 | |||||||||
BB yield | -68.89% | |||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | (1) | |||||||||
Net debt | (29,384) | (44,306) | (52,877) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (14,923) | (8,571) | (14,293) | |||||||
CAPEX | ||||||||||
Cash from investing activities | 483 | (1,000) | ||||||||
Cash from financing activities | 55,122 | |||||||||
FCF | 11,230 | 1,193 | (8,969) | |||||||
| Balance | ||||||||||
Cash | 29,383 | 43,822 | 52,393 | |||||||
Long term investments | 1,000 | 484 | 484 | |||||||
Excess cash | 28,822 | 44,242 | 52,877 | |||||||
Stockholders' equity | (50,385) | (33,987) | (14,549) | |||||||
Invested Capital | 66,787 | 66,781 | 66,783 | |||||||
ROIC | 16.82% | 1.79% | ||||||||
ROCE | 68.47% | 3.87% | ||||||||
| EV | ||||||||||
Common stock shares outstanding | 19,782 | 19,782 | 15,939 | |||||||
Price | 4.56 29.73% | 3.52 -29.98% | 5.02 | |||||||
Market cap | 90,206 29.73% | 69,534 -13.10% | 80,013 | |||||||
EV | 60,822 | 25,227 | 27,136 | |||||||
EBITDA | 11,242 | 1,280 | (8,956) | |||||||
EV/EBITDA | 5.41 | 19.71 | ||||||||
Interest | 129 | 1 | ||||||||
Interest/NOPBT | 10.20% | |||||||||